Premium
P2–392: A pilot randomized double blind controlled study on the efficacy and safety of rivastigmine in Chinese patients with subcortical vascular dementia
Author(s) -
Mok Vincent,
Wong Adrian,
Ho Simon,
Leung Thomas,
Wong Ka Sing
Publication year - 2006
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2006.05.1231
Subject(s) - rivastigmine , placebo , dementia , vascular dementia , medicine , verbal fluency test , psychology , adverse effect , anesthesia , psychiatry , cognition , neuropsychology , donepezil , disease , alternative medicine , pathology
Background We explored the efficacy and tolerability of rivastigmine among Chinese patients with subcortical vascular dementia. Methods Forty subjects were randomized to either placebo (n = 20) or rivastigmine (n = 20) in a double-blind 26-week trial. Outcome measures were cognition (mini-mental state examination, frontal assessment battery), neuropsychiatric inventory (NPI), instrumental activities of daily living, clinical dementia rating scale, and adverse events. Results No statistical significant benefit could be observed in the active group in any of the efficacy measures. A trend favoring active group was observed only in the NPI subscore of irritability (p = 0.066) and aberrant motor behavior (p = 0.068). Withdrawal rate was 30% and 15% in the active and placebo group, respectively. Conclusion Among Chinese subcortical vascular dementia patients, there was no apparent cognitive benefit associated with use of rivastigmine over the 6 months period. A trend favoring rivastigmine was observed in certain behavioral measures. Rivastigmine was associated with more withdrawals relative to placebo.